Logo image of APVO

APTEVO THERAPEUTICS INC (APVO) Stock Fundamental Analysis

NASDAQ:APVO - Nasdaq - US03835L4059 - Common Stock - Currency: USD

3.13  +0.1 (+3.3%)

Fundamental Rating

0

Overall APVO gets a fundamental rating of 0 out of 10. We evaluated APVO against 556 industry peers in the Biotechnology industry. APVO has a bad profitability rating. Also its financial health evaluation is rather negative. APVO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year APVO has reported negative net income.
APVO had a negative operating cash flow in the past year.
In the past 5 years APVO reported 4 times negative net income.
APVO had a negative operating cash flow in each of the past 5 years.
APVO Yearly Net Income VS EBIT VS OCF VS FCFAPVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of APVO (-284.12%) is worse than 92.45% of its industry peers.
Industry RankSector Rank
ROA -284.12%
ROE N/A
ROIC N/A
ROA(3y)-66.85%
ROA(5y)-56.8%
ROE(3y)-200.85%
ROE(5y)-609.94%
ROIC(3y)N/A
ROIC(5y)N/A
APVO Yearly ROA, ROE, ROICAPVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APVO Yearly Profit, Operating, Gross MarginsAPVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, APVO has more shares outstanding
APVO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
APVO Yearly Shares OutstandingAPVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500 1K 1.5K
APVO Yearly Total Debt VS Total AssetsAPVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -51.88, we must say that APVO is in the distress zone and has some risk of bankruptcy.
APVO's Altman-Z score of -51.88 is on the low side compared to the rest of the industry. APVO is outperformed by 92.99% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -51.88
ROIC/WACCN/A
WACCN/A
APVO Yearly LT Debt VS Equity VS FCFAPVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 0.67 indicates that APVO may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.67, APVO is doing worse than 91.19% of the companies in the same industry.
APVO has a Quick Ratio of 0.67. This is a bad value and indicates that APVO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.67, APVO is not doing good in the industry: 90.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.67
APVO Yearly Current Assets VS Current LiabilitesAPVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.13% over the past year.
EPS 1Y (TTM)95.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

APVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.93% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.95%
EPS Next 2Y40.43%
EPS Next 3Y25.59%
EPS Next 5Y14.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APVO Yearly Revenue VS EstimatesAPVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 20M 40M 60M
APVO Yearly EPS VS EstimatesAPVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500K -1M -1.5M -2M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

APVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APVO Price Earnings VS Forward Price EarningsAPVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APVO Per share dataAPVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1K -2K -3K

4.3 Compensation for Growth

APVO's earnings are expected to grow with 25.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.43%
EPS Next 3Y25.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APVO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTEVO THERAPEUTICS INC

NASDAQ:APVO (7/21/2025, 10:27:17 AM)

3.13

+0.1 (+3.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-06 2025-08-06
Inst Owners3.14%
Inst Owner Change0%
Ins Owners0%
Ins Owner Change0%
Market Cap8.95M
Analysts82.86
Price Target428.4 (13586.9%)
Short Float %5.76%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-472.11%
Min EPS beat(2)-942%
Max EPS beat(2)-2.23%
EPS beat(4)2
Avg EPS beat(4)-195.81%
Min EPS beat(4)-942%
Max EPS beat(4)85.97%
EPS beat(8)5
Avg EPS beat(8)-83.21%
EPS beat(12)9
Avg EPS beat(12)2.28%
EPS beat(16)12
Avg EPS beat(16)1.14%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1900%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1900%
EPS NY rev (1m)0%
EPS NY rev (3m)-1900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3326.2
EYN/A
EPS(NY)-295.6
Fwd EYN/A
FCF(TTM)-8.29
FCFYN/A
OCF(TTM)-8.29
OCFYN/A
SpS0
BVpS-0.52
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -284.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.85%
ROA(5y)-56.8%
ROE(3y)-200.85%
ROE(5y)-609.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.67
Quick Ratio 0.67
Altman-Z -51.88
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.81%
EPS Next Y96.95%
EPS Next 2Y40.43%
EPS Next 3Y25.59%
EPS Next 5Y14.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-108.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-109.09%
OCF growth 3YN/A
OCF growth 5YN/A